insurance coverage weight loss drugs
10 Payers Cut Costs 35% With Novo Insurance Coverage
Payers achieve a 35% cost reduction by strategically covering semaglutide and tirzepatide through tiered benefit designs, rebate negotiations, and streamlined claim workflows. The approach aligns clinical outcomes with fiscal stewardship while preserving patient access to high-impact weight-loss therapies. 52% of patients seek semaglutide or tirzepatide, and aligning coverage accordingly boosts